News

Clarus Therapeutics, Inc., today announced the submission of a New
Drug Application (NDA) for Rextoro™ (formerly CLR-610), the
Company’s oral testosterone (T) replacement product, to the
U.S. Food and Drug Administration (FDA).  Efficacy consistent
with the current FDA mandate for T-replacement products was
achieved in two Phase 3 studies.  After protocol-prescribed
dose titration, at least 75% of men treated with Rextoro achieved
average serum T levels (C‑avg) in the normal range (between 300 –
1,000 ng/dL).

By Sabriya Rice

The specter of superbugs spreading through U.S. hospitals has public health experts debating what hospitals should do to deal with such outbreaks. An incident last year in Park Ridge, Ill., may point the way to one approach that could help, according to a report by the Centers for Disease Control and Prevention.

Some 2.5 million people around the world have multiple sclerosis (MS), a potentially debilitating disease in which the body’s immune system destroys the protective sheath (myelin) that covers nerves.

This damage interferes with the communication between the brain, spinal cord and other parts of the body, causing symptoms that can range from a mild weakness to an inability to walk or speak clearly. There is no cure for MS, but there are some preliminary data showing that Vitamin D, retinoic acid or Vitamin A, may help alleviate these symptoms.

Brad Spellberg is a professor of medicine at the Los Angeles Biomedical Research Institute at Harbor-U.C.L.A. Medical Center. He is the co-author of “Rising Plague: The Deadly Threat from Deadly Bacteria and Our Dwindling Arsenal  to Fight Them.”

Sandy Mazza, Daily Breeze

The ASCO Post

By Caroline Helwick
December 15, 2013, Volume 4, Issue 20

According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the 2013 European Cancer Congress byRowan T. Chlebowski, MD, PhD, Professor and Chief of Medical Oncology/Hematology at the David Geffen School of Medicine at UCLA and Harbor-UCLA Medical Center, Los Angeles.1

Important Findings

LOS ANGELES – (Dec. 5, 2013) – In a finding that could expand the use of one of the most effective forms of birth control, two intrauterine contraceptive systems that had lower doses of the contraceptive hormone, levonorgestrel, were found to be safe and effective in preventing pregnancies, according to an international study that included researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).

The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) will honor one of the Palos Verdes Estate’s leading businessmen and philanthropists, Ralph Scriba, with its Award for Community Service, and one of its most distinguished researchers, Kouichi R. “Corky” Tanaka, MD, of Rancho Palos Verdes, with its Award for Inspirational Leadership at the institute’s Translating Science and Transforming Lives Gala Dec. 5 at the Beverly Wilshire Hotel in Beverly Hills.

A new study found that men who live the longest are those who have medium testosterone levels. High or low testosterone levels are linked to reduced mortality. Testosterone is a key male sex hormone involved in maintaining sex drive, sperm production and bone health. Physicians have long known that low testosterone levels can signal health problems, but the new study found men may not fare better when levels of the hormone rise too high.

American Lung Association report reveals that women are at greater risk than men

W omen are 37 percent more likely to have chronic obstructive pulmonary disease (COPD) than men and now account for more than half of all deaths attributed to COPD in our nation. The American Lung Association’s latest health disparity report, “Taking Her Breath Away: The Rise of COPD in Women,” examines the nation’s third leading cause of death and its increased prevalence among women throughout the U.S.